CERO · Cero Therapeutics Holdings, Inc. · Shareholders & Ownership
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Every disclosed holder of CERO in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns CERO
13F quarter Jun 30, 2026| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 2,500 | 0.00% |
| Insiders (Forms 3, 4, 5) | 0 | 0.00% |
| 13D/G-only blocks | 99,949 | 0.14% |
| Remaining | 71,528,543 | 99.86% |
| Registered funds (N-PORT, not summed) | 0 | 0.00% |
Shares outstanding: 71,630,992, the issuer's latest cover-page count restated onto today's split basis.
Insiders are listed but not summed: the issuer has more than one class of common stock and Forms 3, 4 and 5 report one issuer-wide balance across them.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of CERO
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
ARMISTICE CAPITAL, LLC
13G
CIK 1601086 · Registered investment adviser · Jun 30, 2025
Rule 13d-1(b), qualified institution
|
63,308 | ||
| 2 |
Brian G. Atwood
13D
CIK 1266567 · Unknown · Mar 31, 2025
|
25,590 | ||
| 2.1 |
|
24,590 | ||
| 3 |
Ancora Advisors LLC
13F
CIK 1446114 · Registered investment adviser · Jun 30, 2026
|
2,500 | ||
| 4 |
Jurgen van de Vyver
13D
CIK 1870407 · Unknown · Feb 14, 2024
|
508 | ||
| 5 |
YK Bioventures Opportunities GP I, LLC
13G
CIK 2042634 · Unknown · Dec 13, 2024
Rule 13d-1(c), passive investor
|
9 | ||
| 5.1 |
YK Bioventures Opportunities GP I, LLC
Insider
CIK 2042634 · Dec 13, 2024
10% Owner, issuer-wide, not summed
|
6,503 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.